Latest research on Abacavir

Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. [Wikipedia] Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.

Latest findings

In the SINGLE study, treatment-naïve patients were randomized to receive either Abacavir (ABC)/3TC/DTG or TDF/FTC/EFV for 96 weeks [8]. [source, 2016]
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, an international collaboration representing over 30,000 HIV-infected patients across Europe, the United States, and Australia, found an increased risk of myocardial infarction with use of PIs and certain NRTIs, namely, Abacavir and Didanosine [45, 49–51]. [source, 2016]
Of the 4831 pregnancies for which nucleoside reverse transcriptase inhibitor (NRTI) backbone therapy data were available, Zidovudine (ZDV) + lamivudine (3TC), Emtricitabine (FTC) + tenofovir (TDF), and Abacavir (ABC) + 3TC were the most common, accounting for 85 % (4106/4831) of all backbone therapy regimens administered. [source, 2016]
Among certain drugs which are known to develop SJS/TEN and be associated with specific HLA-allele, Allopurinol, was the most commonly described and used drug (16.5%), followed by carbamazepine (0.4%), Lamotrigine (0.4%), and Abacavir (0.2%) (Table 1). [source, 2016]
However, among Abacavir users, no one developed SJS/TEN. [source, 2016]
Abacavir, Lamivudine and Nevirapine were commenced and the VL suppressed to 270 copies /mL (Log10 2.4) at 12 weeks. [source, 2016]
This virus, showed high-level resistance to Lamivudine and Nevirapine and low-level resistance to Abacavir. [source, 2016]
Highly active antiretroviral therapy (HAART) was changed to Abacavir, Lamivudine, Zidovudine and boosted atazanavir. [source, 2016]
Past history included subcutaneous injection of esthetic filler material in the lower legs 20 years ago, hypothyroidism and HIV infection on highly active antiretroviral therapy (HAART: raltegravir, Abacavir, Lamivudine). [source, 2016]
However, compared with earlier NRTIs, the rate of lipoatrophy with newer NRTIs (eg, TDF and Abacavir) appears to be low, making it unclear whether NRTI-sparing regimens will have much clinical impact. [source, 2016]